

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 147 770 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

24.10.2001 Bulletin 2001/43

(51) Int Cl.7: **A61K 31/42**, A61K 38/15,
A23K 1/17

(21) Application number: **01118965.1**

(22) Date of filing: **05.06.1997**

(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE**

Designated Extension States:

SI

- **Chapin, Frederic William Pat.Dept.Pfizer Global Groton, Connecticut 06340 (US)**
- **Fahrenholz, Charles Hollett Pat.Dept.Pfizer Groton, Connecticut 06340 (US)**

(30) Priority: **01.07.1996 US 20512 P**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

97922002.7 / 0 906 098

(74) Representative: **Hayles, James Richard
Pfizer Limited,
European Patents Department,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)**

(71) Applicant: **PFIZER INC.**

New York, N.Y. 10017 (US)

Remarks:

This application was filed on 06 - 08 - 2001 as a divisional application to the application mentioned under INID code 62.

(72) Inventors:

- **Carson, James William
Pat.Dept.Pfizer Global Res.
Groton, Connecticut 06340 (US)**

(54) **Virginiamycin mixture**

(57) A mixture comprising: a) virginiamycin; b) a pharmaceutically acceptable and substantially anhydrous wetting agent including sodium lauryl sulfate; c) a sufficient amount of pharmaceutically acceptable buffering agent to provide a pH of from about 3.0 to about 7.0 when said mixture is added to water; and d) from

about 0.5 weight percent to about 10.0 weight percent colloidal silicon dioxide, wherein the ratio of the weight percent of (b) to the weight percent of (a) percent by weight is at least about 1.5:1. The mixture is designed to be added to water to produce a stable suspension of the virginiamycin, which can then be applied to, for example, feed grain.

EP 1 147 770 A1

DescriptionBackground of the Invention

5 **[0001]** The present invention relates to a mixture comprising virginiamycin.

[0002] Virginiamycin antibiotics, in their most effective form, include both M and S components. Coccito, *Micro. Rev.*, 43, 145 (1979). Virginiamycin has been used as an antibacterial and in the prevention of lactic acidosis (e.g. United States Patents 5,137,900 and 5,242,938 and The Merck Index, 12th Edition, pages 1707-1708). It has also been used in the form of a feed additive to improve growth in poultry, swine, and cattle. A possible mechanism for its use as a growth promotant could relate to an inhibition of intestinal flora. Coccito, *supra*. Virginiamycin's widely accepted use stems from having low toxicity, minimal production of resistant mutant strains, quick degradation in feces, and minimal tissue retention.

[0003] Wettable powders have been used for the administration of various insecticides and herbicides.

15 Summary of the Invention

[0004] The present invention relates to a mixture comprising:

a) virginiamycin;

20 b) a pharmaceutically acceptable surfactant including sodium lauryl sulfate;

c) a sufficient amount of pharmaceutically acceptable buffering agent to provide a pH of from about 3.0 to about 7.0 when said mixture is added to water; and

d) from about 0.5 weight percent to about 10.0 weight percent colloidal silicon dioxide,

25 **[0005]** wherein the ratio of the weight percent of (b) to the weight percent of (a) is at least about 1.5:1.

Detailed Description

30 **[0006]** The mixture comprising virginiamycin is in the form of a wettable-type powder. The powder mixture can be added to water, including some forms of hard water, to produce a stable suspension of the virginiamycin, which can then be, for example, delivered directly to a patient (e.g orally) or applied to, for example, food stuffs such as feed grain. The feed grain is then fed to animals, for example livestock and poultry, thereby administering the virginiamycin. The mixture should preferably be substantially anhydrous so as to maximize the shelf life of the mixture prior to forming the water suspension.

35 **[0007]** Virginiamycin can be produced using known methods, for example, fermentation. For example, virginiamycin M can be produced by fermentation of a streptomyces species originally isolated from Indian soil samples and deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, United States of America on July 29, 1986 and assigned ATCC number 53527, United States Patent 5,242,938.

40 **[0008]** Dose levels of virginiamycin are known in the art and can vary due to a number of factors, including, for example, compound activity, the route of administration, the time of administration, disease severity, excretion rate, combination of other drugs, as well as the age, body weight, sex, diet, and general health of the patient being treated. Generally, for example, with a human subject, the daily effective dose can range from about 1.0 mg to about 1500 mg, preferably about 10 mg to about 500 mg, in single or divided doses. For a domestic animal, the effective dose can range from about 5 to about 200 parts per million per volume of food. United States Patent 5,242,938.

45 **[0009]** For veterinary purposes, dosage levels known in the art can also be found, for example, in the 1996 Feed Additive Compendium, Miller Publishing Co. (1996), pp. 324-328.

[0010] The claimed mixture comprises virginiamycin, preferably substantially pure, and a pharmaceutically acceptable surfactant, sodium lauryl sulfate (SLS), preferably substantially anhydrous and granulated. The ratio of the weight percent of SLS to the weight percent of virginiamycin should be at least about 1.5 to 1, preferably about 1.54 to 1. Substantially pure virginiamycin has an activity of about 200% (plus or minus 20%) as measured by methods known in the art (Gossele, et al., *Analyst*, 116, 1373 (1991) and Blain, et al., *Analyst*, 119, 361 (1994)).

50 **[0011]** The powder mixture also includes a pharmaceutically acceptable anti-caking agent, colloidal silicon dioxide, which can act as scavenger for water as well as a wetting and suspending agent for the virginiamycin. The amount of colloidal silicon dioxide can range from 0.5 weight percent of the mixture to about 10.0 weight percent of the mixture, preferably about 2.0 weight percent.

55 **[0012]** A pharmaceutically acceptable buffer is also included, for example phosphate or citrate buffers, preferably citric acid/sodium citrate. The amount of buffer should be sufficient to provide a pH of from about 3.0 to about 7.0, preferably from about 4.0 to about 5.5 when the mixture is added to water. Maintenance of pH permits the virginiamycin

to be suspended in a water environment with minimal effect on its activity.

[0013] The powder mixture is added to water to form a stable suspension of the virginiamycin, which is then applied to, for example, feed grain. The amount of mixture dispensed in the water is approximately 4.5% by weight of the suspension.

[0014] A pharmaceutically acceptable water soluble filler material can also be included. Examples include sugars, such as lactose and dextrose, preferably lactose. Such fillers may also effect the flowability of the mixture.

[0015] A pharmaceutically acceptable anti-foaming agent, which is, for example, an emulsion and will not substantially effect the pH of the resulting suspension, can also be included in the anhydrous mixture, for example, polydimethylsiloxane. Once the suspension is made, the anti-foaming agent minimizes the amount of foam caused by the SLS upon agitation of the suspension. This can be important if, for example, the suspension is being sprayed and a pump is needed to drive the suspension through the spraying apparatus. The amount of anti-foaming agent in the mixture can range from about 0.5 weight percent to about 10.0 weight percent, preferably about 2.8 weight percent.

[0016] The mixture should preferably be maintained as substantially anhydrous prior to forming the suspension in order to minimize the breakdown of the components of the mixture. As a result of minimizing breakdown, the shelf life of the mixture can be maximized.

[0017] The mixture is formed by adding its ingredients together and thoroughly blending them together. Once the mixture is formed, a suspension can be made by adding the mixture to water. The resulting suspension is substantially stable with minimal sedimentation of virginiamycin falling out of the suspension for about a day with periodic stirring or with little or no stirring of the suspension for about a couple hours, preferably about six hours once the suspension has been properly formed.

[0018] A pharmaceutically acceptable indicator dye can also be included, depending upon acceptable food and drug regulations. The dye, for example, FD&C blue No. 1 powder, would give a blue color to the suspension and, in turn, to feed grain sprayed therewith. Thus, the treated grain can be readily identified.

[0019] A preferred formulation of the claimed invention is the following:

INGREDIENT	FORMULA	% W/W
Virginiamycin Feed Grade* (activity = about 200%)	not available	18.8
Sodium Lauryl Sulfate	$C_{12}H_{25}NaO_4S$	30.0
Colloidal Silicon Dioxide	SiO_2	2.0
Citric Acid, anhydrous, fine granular	$C_6H_8O_7$	20.0
Sodium Citrate anhydrous powder	$C_6H_5N_{23}O_7$	20.0
Antifoam AF emulsion	$[-(CH_3)_2SiO_2]_n$	2.8
FD&C Blue No. 1 powder	FDA Lot # AG4275 Wamer-Jenkinson Co. Code # 05601	0.4
Lactose* anhydrous, 80 mesh	$C_{12}H_{22}O_{11}$	6.0

* Virginiamycin and lactose calculated to provide 40% virginiamycin activity. Amounts will vary depending on purity of virginiamycin.

[0020] The following are intended as non-limiting examples of the present invention.

Example 1

[0021] The below listed ingredients were combined and mixed together until a uniform mixture was formed.

INGREDIENT	% w/v	AMOUNT
Virginiamycin Feed Grade 213%	0.94	9.40g
Sodium Lauryl Sulfate	1.50	15.00g
Colloidal Silicon Dioxide	0.10	1.00g
Citric Acid U.S.P.	1.00	10.00g
Sodium Citrate U.S.P.	1.00	10.00g
Antifoam A.F.	0.10	1.00g

EP 1 147 770 A1

[0022] A suspension was formed by adding the above mixture to 900 ml of distilled water in a 1 liter graduated cylinder until dispersion was complete. Then additional water was added to bring the total volume to 1 liter, pH 4.24.

Example 2

[0023] The below listed ingredients were combined and mixed together until a uniform mixture was formed.

INGREDIENT	% w/v	AMOUNT
Virginiamycin Feed Grade 213%	0.94	9.40g
Sodium Lauryl Sulfate	1.50	15.00g
Colloidal Silicon Dioxide	0.10	1.00g
Citric Acid U.S.P.	1.00	10.00g
Sodium Citrate U.S.P.	1.00	10.00g
Antifoam A.F.	0.10	1.00g

[0024] A suspension was formed by adding the above mixture to 900 ml of distilled water in a 1 liter graduate until dispersion was complete. Then additional water was added to bring the total volume to 1 liter. pH 4.30.

Example 3

[0025] The below listed ingredients were placed in a mixer and mixed for 15 minutes to form a base mixture.

INGREDIENT	% w/v	AMOUNT
Sodium Lauryl Sulfate	36.9	4500.0 g
Citric Acid	24.6	3000.0 g
Sodium Citrate	24.6	3000.0 g
Anhydrous Lactose, 80 Mesh (Sheffield)	7.4	900.0 g
Antifoam A. F. Emulsion	3.4	420.0 g
Colloidal Silicon Dioxide	2.6	300.0 g
FD&C Blue No. 1 Powder	0.5	60.0 g

A. 1126.8 g of virginiamycin animal feed grade (213% activity) (18.8%) was added to 4873.2 g of base mixture (81.2%) in a mixer and mixed for 15 minutes.

B. 956.1 g of virginiamycin animal feed grade (205% activity) (19.5%) was added to 3943.2 g of base mixture (80.5%) in a mixer and mixed for 15 minutes.

Claims

1. A mixture comprising:

- virginiamycin;
- a pharmaceutically acceptable surfactant including sodium lauryl sulfate;
- a sufficient amount of pharmaceutically acceptable buffering agent to provide a pH of from about 3.0 to about 7.0 when said mixture is added to water; and
- from about 0.5 weight percent to about 10.0 weight percent colloidal silicon dioxide,

wherein the ratio of the weight percent of (b) to the weight percent of (a) percent by weight is at least about 1.5:1.

2. The mixture of claim 1, further including a pharmaceutically acceptable anti-foaming agent.

3. The mixture of claim 1, further including a pharmaceutically acceptable dye.

4. The mixture of claim 1, wherein said mixture is substantially anhydrous.

5. Feed grain treated with a water suspension of a mixture comprising:

a) virginiamycin;

b) a pharmaceutically acceptable surfactant including sodium lauryl sulfate;

c) a sufficient amount of pharmaceutically acceptable buffering agent to maintain said suspension at a pH of from about 3.0 to about 7.0;

d) from about 0.5 weight percent to about 10.0 weight percent colloidal silicon dioxide,

wherein the ratio of the weight percent of (b) to the weight percent of (a) percent by weight is at least about 1.5:1.

6. The feed grain of claim 5, said mixture further including a pharmaceutically acceptable dye.

7. The feed grain of claim 5, further including a pharmaceutically acceptable anti-foaming agent in said mixture.

8. A method of treating feed grain with virginiamycin, comprising

(1) forming a mixture including:

a) virginiamycin,

b) a pharmaceutically acceptable surfactant including sodium lauryl sulfate,

c) a sufficient amount of pharmaceutically acceptable buffering agent to provide a pH of from about 3.0 to about 7.0 when said mixture is added to water, and

d) from about 0.5 weight percent to about 10.0 weight percent colloidal silicon dioxide, wherein the ratio of the weight percent of (b) to the weight percent of (a) percent by weight is at least about 1.5:1;

(2) suspending said mixture in water to form a suspension; and

(3) applying said suspension to feed grain.

9. The method of claim 8, further including a pharmaceutically acceptable anti-foaming agent in said mixture.

10. The method of claim 8, further including a pharmaceutically acceptable dye in said mixture.

11. The method of claim 8, further including drying the feed grain after the applying step.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 11 8965

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	BE 819 863 A (RECHERCHE ET INDUSTRIE THERAPEUTIQUES, R.I.T.) 13 March 1975 (1975-03-13) * page 2, line 20 - line 31 *	1,5	A61K31/42 A61K38/15 A23K1/17
Y	EP 0 614 910 A (RHONE-POULENC RORER S.A.) 14 September 1994 (1994-09-14) * example C *	1,5	
Y	EP 0 616 841 A (KANEKAFUCHI KAGAKU KOGYO K.K.) 28 September 1994 (1994-09-28) * claims 1,4 *	1,5	
A	US 5 266 347 A (BRUCE D. KING) 30 November 1993 (1993-11-30)		
A	WO 95 11598 A (LACHLAN MACSMITH) 4 May 1995 (1995-05-04)		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K A23K
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 29 August 2001	Examiner Alvarez Alvarez, C
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 03.82 (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 11 8965

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-08-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
BE 819863	A	13-03-1975	FR 2284318 A	09-04-1976
EP 614910	A	14-09-1994	AP 520 A	26-08-1996
			FR 2701709 A	26-08-1994
			WO 9605219 A	22-02-1996
			AT 406052 B	25-02-2000
			AT 30594 A	15-06-1999
			AU 678785 B	12-06-1997
			AU 5510094 A	25-08-1994
			BE 1006554 A	11-10-1994
			CA 2115807 A	18-08-1994
			CH 688588 A	28-11-1997
			CZ 9400326 A	14-09-1994
			CZ 285281 B	16-06-1999
			DE 69414622 D	24-12-1998
			DE 69414622 T	17-06-1999
			DK 614910 T	02-08-1999
			ES 2081763 A	01-03-1996
			FI 940717 A	18-08-1994
			GB 2275269 A,B	24-08-1994
			GB 2301821 A,B	18-12-1996
			GR 94100078 A,B	31-10-1994
			HK 1006500 A	14-04-2000
			HK 1006499 A	17-03-2000
			HU 66821 A	30-01-1995
			IE 940144 A	24-08-1994
			IL 108641 A	27-12-1998
			IT 1269214 B	21-03-1997
			JP 6298664 A	25-10-1994
			LU 88454 A	01-12-1994
			MX 9401171 A	31-08-1994
			NO 940533 A	18-08-1994
			NZ 250884 A	21-12-1995
			PL 302250 A	22-08-1994
			PL 175020 B	30-10-1998
			PL 175016 B	30-10-1998
			PT 101460 A,B	30-09-1994
			SK 18494 A	08-02-1995
			US 5726151 A	10-03-1998
			US 5637565 A	10-06-1997
			ZA 9401024 A	25-08-1994
			IL 121821 A	17-02-2000
			BR 1101176 A	07-12-1999
			BR 9408613 A	16-09-1997
EP 616841	A	28-09-1994	DE 69322764 D	04-02-1999

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 11 8965

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-08-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 616841 A		DE 69322764 T	06-05-1999
		US 5547683 A	20-08-1996
		CA 2124568 A	28-04-1994
		CN 1091628 A	07-09-1994
		ES 2124794 T	16-02-1999
		WO 9408709 A	28-04-1994
US 5266347 A	30-11-1993	BR 9307906 A	27-08-1996
		WO 9514395 A	01-06-1995
		AU 5731794 A	13-06-1995
		EP 0730413 A	11-09-1996
		DE 69329952 D	29-03-2001
		DE 69329952 T	09-08-2001
		JP 9511123 T	11-11-1997
		PL 314694 A	16-09-1996
WO 9511598 A	04-05-1995	AU 680311 B	24-07-1997
		AU 7986394 A	22-05-1995